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Summary. Even though rhabdomyosarcoma is the most 
common soft tissue sarcoma in children, accounting for 
5-10% of all malignant disease in children under 15 years 
of age, so few cases are seen in a single institution that 
only the combined efforts of multicentre prospective trials 
made it possible fro adequate treatment schedules to be 
devised. Thank to this cooperation, survival rates have in­
creased dramatically in recent decades; risk factors have 
been identified and treatment can now be adapted accord­
ingly. This is especially true for the paratesticular rhab­
domyosarcoma (PTRM), which now has a good prognosis 
in all stages. The striking similarity of tumor behavior and 
metastatic pathways to those in germ-cell tumors in young 
male adults can provide us with more extensive data de­
rived from a much larger group of patients. Recent data 
are gathered and evaluated in this review. Only in this way 
will it be possible to eliminate all treatment modalities 
known to be followed by severe sequelae, thus avoiding 
exposure of the patients to a therapy that carries more 
risks than the primary tumor itself.
Rhabdomyosarcoma is the most common soft tissue sar­
coma of childhood, representing 5-10% of all malignant 
tumors in children [25]. Only neoplasms of the brain, 
lymphomas, neuroblastomas and Wilms5 tumors are more 
frequently seen [24], Of all rhabdomyosarcomas, 13-20% 
develop in the urogenital tract [17], They all originate from 
the same embryonal mesenchyme, which is universally pre­
sent in the embryo and differentiates into striated muscle.
The annual incidence is 4.5 individuals per million in 
the white population, whereas the black race has an inci­
dence of 1.3 per million children. The female-to-male ra­
tio is 1:3. It has been associated with other congenital dis­
orders related to the nervous system like neurofibromato­
sis and familial coincidence with sarcomas and breast 
cancers has been described. Much of this is indicative of 
the existence of a possible genetic factor in these tumors, 
as in children with Wilms’ tumors [27].
From 7% to 10% of all rhabdomyosarcomas arise from 
the distal spermatic cord: these are the paratesticular rhab­
domyosarcomas (PTRM). In this location the tumor might 
invade the testis, the surrounding envelopes, the epididymis
and the vestigial remnants [8, 24]. PTRM show the high­
est rate of metastatic involvement of the regional lymph 
nodes. From 26% to as much as 71% of the patients pre­
senting with a PTRM show involvement of the para-aortic 
and or paracaval nodes [13, 24]. At the time of diagnosis 
about 20% have distant métastasés to the lungs, cortical 
bone or, more rarely, to the bone marrow [28]. Genitouri­
nary rhabdomyosarcomas can be subdivided by anatomi­
cal location: paratesticular, bladder and/or prostate in male 
patients and uterine vaginal and/or vulvar in female pa­
tients; in addition another subdivision can be made ac­
cording to the histology: favorable and unfavorable.
The unfavorable histological types show enlarged ac­
tive structures with diffuse nuclear hyperchromatism and 
pleomorphism or monomorphous round cell types with a 
very regular size distribution and similar cytological char­
acteristics throughout the tumor or an alveolar pattern. 
The group with favorable histology is constituted mainly 
of tumors the embryonal cell type, reflecting the primitive 
cell and all other cellular configurations not belonging to 
the unfavorable group [6, 28]. Most PTRM (97%) belong 
to the favorable histology group of embryonal cell type 
tumors [13, 18].
Up to the first half of this century the prognosis was 
uniformly bad for all rhabdomyosarcomas. Campbell was 
not able to present a single long-term survivor in his ex­
tensive overview in 1951. Adequate treatment was impos­
sible, and relief of tumor-related symptoms was all that 
could be offered to these children, in whom the suprapu­
bic region was often opened to allow the tumor to grow 
with less pain to the patients. Paratesticular tumors were 
described as sarcoma, fibrosarcoma and myxosarcoma, 
and of the seven cases collected from the literature two 
possibly survived at least in the short term [5J.
The earliest treatment applied was surgery, which had 
to be very radical and mutilating to offer any chance at all. 
Radiotherapy was started in the late 1940s, soon to be fol­
lowed by and combined with the administration of single 
cytotoxic drugs. The advent of chemotherapy raised the 
survival rate considerably.
Multi center coordinated studies were started in the early 
1970s, with the Intergroup Rhabdomyosarcoma Study (1RS) 
in 1972 and the rhabdomyosarcoma studies of the Inter­
national Society of Paediatric Oncology (SIOP) in 1975.
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Table 1. Differential diagnosis of space- 
occupying paratesticular lesions in children
Malignant Benign
Primary Metastatic Non-tumorous Tumorous
Germ cell tumors 
Yolksac
T eratocarcinoma 
Seminoma
Lymphoma
Leukaemia
Hydrocele 
Torsio testis 
Idiopathic 
Lymphedema
Adenomatoid
tumors
Lipoma
Leiomyoma
Gonadal stromal tumors
Sertoli cell 
Leydig cell
Juvenile granulosa cell
Rhabdomyosarcoma
Fibrosarcoma
Leiomyosarcoma
Liposarcoma
Epididymal
Adenocarcinoma
Epididymitis 
(Viral) orchitis
Epidermoid cysts
Teratoma 
1pi* 1
Fibroma
Hemangioma
Neurofibroma
These combined efforts resulted in multidrug therapy with 
or without radiotherapy, with a survival rate now of 70- 
80% for all rhabdomyosarcomas in the urogenital area
and up to 90% of PTRM [13, 23, 31].
Diagnostic work-up
Early diagnosis of the lesion is one of the most important 
prognostic factors in these tumors, which normally ex­
hibit aggressive behavior.
Paratesticular tumors are generally detected more read­
ily than those located in the bladder, prostate or vagina, as 
there are easily recognizable symptoms, such as a painless 
swelling in the groin or a mass in the scrotum; it is impor­
tant to exclude testicular torsion, hydrocele and epi­
didymitis. This results in a lower grading of this type of 
tumor at time of diagnosis: 60% of paratesticular tumors 
are diagnosed in stage I, as against only 13% in the over­
all population in IRS studies I and II (P < 0.001) [31].
Ultrasound investigation should be the first study per­
formed in a child presenting with a testicular lesion. There 
is a high correlation between clinical suspicion of PTRM 
and an ultrasonography revealing the nature of the tumor 
as solid, semi-solid or cystic. It defines the exact size of 
the tumor and is highly reliable in revealing whether or 
not the testis itself is involved.
Since the incidence of nodal involvement is high in 
this subtype of rhabdomyosarcoma, attention should be 
focused on whether or not this is present at the time of di­
agnosis, to allow selection of the most appropriate follow- 
up therapy. The bipedal lymphangiography, which has a 
morbidity rate of 7-lG% and an accuracy rate of 40-94%, 
has been superseded almost everywhere by the CT scan, 
which has an accuracy rate of 81-91% and involves no 
morbidity at all [7]. The only disadvantage of the latter 
technique is the fact that it is unable to differentiate be­
tween benign enlargement of the nodes caused by inflam­
mation and malignant enlargement caused by metastasis. 
Further investigations are chest X-ray (or CT), bone mar­
row aspiration and radioisotope bone scan with X-ray 
evaluation of suspected sites. The results of these studies 
differentiate between patients with and those without 
metastatic disease and show the probability of more ex­
tensive nodal involvement.
The next step must be histological confirmation of the 
malignancy, especially since only between 12% and 22% 
of all space-occupying lesions in the paratesticular site 
will be malignant [15, 31] (Table 1).
All studies and protocols recommend radical inguinal 
removal of the primary tumor (orchiectomy) as the first 
step with vascular control during the procedure. Biopsies 
should be avoided, but if necessary all precautions should 
be taken to avoid tumor spill and contamination by drap­
ing off the entire operative field during this procedure.
Transscrotal manipulation or biopsies are absolutely 
contraindicated because of the likelihood of contamina­
tion of this operative route by tumor rupture. These pro­
cedures can change the stage from a low-risk category to 
a high-risk one with all the implications this has for ther­
apy. The radical inguinal orchiectomy should be extended 
■ to the internal inguinal ring. In the case of involvement of 
scrotal tissue, e.g., ingrowth or even firm adhesions, and 
after transscrotal biopsies a hemi-scrotectomy of the in­
volved side should be performed [31].
Bunge et al.’s [4] observation of a scrotal recurrence 
5 years after orchiectomy for PTRM in an undescended 
testicle that had previously been operatively corrected 
confirms the inclination of this tumor to local growth. It 
also raises the question of whether or not a hemiscrotec- 
tomy should be performed routinely in all cases of opera­
tively corrected undescended testicles in case of a PTRM. 
Whether or not this first surgical intervention should be 
extended by a selective node biopsy, or a formal selective 
retroperitoneal lymph node dissection (RPLND) is still a 
hotly debated issue.
In the first three studies conducted by the IRS (1972- 
1991) a lymphadenectomy was recommended in all cases. 
This was based on the high incidence of lymph node in­
volvement presented in many studies, which was very
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Table 2. Intergroup Rhabdomyosarcoma Study: clinical grouping
Clinical Definition
grouping
] Localized disease, completely resected
(a) Confined to muscle or organ of origin
(b) Contiguous involvement (infiltration outside the 
muscle or organ of origin, as through fascial 
planes)
II Total gross resection with evidence of regional spread
(a) Grossly resected tumor with microscopic residual 
disease
w
(b) Regional disease with involved nodes, completely 
resected with no microscopic residual disease
(c) Regional disease with gross resection of involved 
nodes, but with evidence of microscopic residual 
and/or histological involvement of the regional 
node most distal to the primary site
III Incomplete resection with gross residual disease
(a) After biopsy only
(b) After gross or major resection of < 50% the 
primary tumor
IV Distant metastatic disease present at onset
similar to the rates known in testicular germ-cell tumor. 
Paratesticular and testicular structures show a similar 
lymph drainage pattern to those in the para-aortic and 
para-iliac nodes [13, 19, 24, 31].
One of the points to be taken into account in the stud­
ies cited above is the different staging systems that have 
been used. One group uses the IRS classification [6, 17, 
27, 28, 31]; the other group uses the SIOP TNM classifi­
cation, as we did in our study [13, 19, 30]. With the clini­
cal classification system of the IRS (Table 2) the most im­
portant prognostic parameter is the fact whether or not a 
complete surgical removal was accomplished. The pa­
tients are then divided into clinical groups accordingly.
The SIOP, TNM system emphases the invasiveness of 
the tumor and the nodal status at the time of diagnosis, us­
ing this in combination with the primary tumor site to di­
vide patients in treatment groups (Tables 3-5),
According to Pedrick et al. [21], who conducted an ex­
tensive comparative study between the two different stag­
ing systems in a retrospective study of 84 consecutive 
newly diagnosed patients with rhabdomyosarcoma, the 
TNM system provided the best differentiation of the pa­
tients in accordance to long-term outcome.
The most impressive difference between the two sys­
tems was seen in the stage III group, in which the major­
ity of patients (53 of 74 or 72%) were classed according to 
the IRS system and only 28 of 74 (38%) according to the 
TNM system. On the other hand, the 9 stage I patients 
(TNM system) originated in almost equal numbers from 
IRS groups I, II and III. This obviously would have had a 
great impact on the consequent therapy for the individual 
patient, had this been a prospective study.
Pedrick et al. concluded that the clinically based TNM 
system differentiated the patients more adequately in rela­
tion to prognostic relevant factors than the IRS system
Table 3. TNM classification
SIOP (RM group)
T Primary tumor
pT Primary tumor
Tumor node metastasis system
Clinical
TO No evidence of tumor
T1 Tumor confined to the organ tissue of origin 
A: Tumor > 5 cm 
B; Tumor > 5 cm
T2 Tumors involving one or more contiguous 
organs or tissues or with malignant effusion
A; Tumor > 5 cm 
B: Tumor > 5 cm
N Regional lymph nodes No No evidence of regional lymph node involvement
N1 Evidence of regional lymph node involvement 
Nx Requirements to assess the involvement cannot be met
Surgical
pTO No tumor
PT1 Tumor limited to organ or tissue 
of origin. Excision complete and margins 
histologically free
PT2 Tumor with invasion beyond the 
organ or tissue of origin. Excision 
complete and margins histologically free
PT3 Tumor with or without invasion 
beyond the organ or tissue of origin.
Excision incomplete
PT3a Evidence of microscopic residual tumor
pT3b Evidence of macrosopic residual 
tumor or biopsy only
pT3c Adjacent malignant effusion 
regardless of the size
M Distant métastasés MO No evidence of distant metastasis
M l Evidence of distant metatsasis
Mx Requirements to assess the presence cannot be met
i
i
Table 4. TNM staging of SIOP RM group
Stage 1 Tla, T ib NO MO
Stage II T2a, T2b NO MO
Stage 111 Any T> any N MO
Stage IV Any T, any N M l
Table 5. SIOP clinical grouping for therapy
Group Tumor status
A T1 NO MO PT1
T2 NO MO PT2 or PT3 a,b,c
c Stage II
E Stage III and stage IV
could, the T status being the most important factor. This 
was confirmed by Lawrence et al. [14], who performed an 
extensive study in over 500 patients in the IRS II study. 
Since then the regularly held international rhabdomyosar­
coma workshops have been held regularly and a pretreat­
ment TNM staging system has been agreed on.
Therapy
The therapeutic regimens have changed over time accord­
ing to the outcome of the multicentre studies, which have 
extended knowledge of the prognostic factors and of the 
biological behavior of the PTRM and their sensitivity to 
different chemotherapeutic or radiotherapeutic regimens
[13,23,27, 28,31].
In 1RS I (all rhabdomyosarcomas) the survival results 
of children treated with radiotherapy and different cyto­
toxic regimens and with two different routes of adminis­
tration of the drugs were evaluated. One of the conclu­
sions was that radiation therapy had no additional benefit 
in group I (1RS) patients. 1RS II showed that chemother­
apy alone did not yield the same good result as in the first 
study without adjuvant surgery and radiotherapy. The 1RS 
III study evaluated different chemotherapeutic regimens 
and raised the question as to whether second- and third- 
look surgery would improve the final local tumor control.
The ongoing study, 1RS IV, will evaluate the additional 
value of lymph node sampling in the case of clinical sus­
picion of node involvement and possible further restric­
tion of radiotherapy regimens in combination with the es­
tablished chemotherapeutic schemes. The present thera­
peutic scheme of the 1RS group related to the clinical 
group is shown in Table 6.
The SIOP study (all rhabdomyosarcomas) from 1971 
to 1984 shows two periods with a different approach [19, 
26]. The patients in the first period (1971-1975) received 
maximal chemotherapy, surgery and radiotherapy. Fol­
low-up showed severe sequelae. From 1975-1984 regi­
mens were developed that involved treating all patients 
with chemotherapy and, depending on the results of eval­
uation, also with selective surgery or radiotherapy (except 
al] stage I pTINOMO patients); in this part of the study
Table 6. IRSa Therapeutic Scheme for PTRM
Group Therapy
I Vincristine and actinomycin D for 1 year
llb Vincristine, actinomycin D plus cyclophosphamide versus
vincristine, actinomycin D plus ifosfamide for 1-2 years
plus radiation therapy to involved region
IIIb 3- to7-drug regimen plus radiation therapy to involved
region
IV Same as group III
51 IRS IV study
b Radiation can be conventional (II) or conventional versus hyper-
fractionated (III)
Table 7. SIOP (RM group) therapeutic scheme for PTRM
G roup Therapy
A Two courses of vincristine and Actinomycin SD (pulse)
in 9 weeks
B Four courses of ifosfamide, vincristine and actinomycin
D (IVA, pulse) Radiotherapy only after failed surgery
(gross) and failed chemotherapy (2 courses) Otherwise
second-line chemotherapy
C Six courses of IVA (pulse) Radiotherapy only after failed
surgery (microscopic) and failed chemotherapy (4 or
6 courses) Otherwise second-line chemotherapy
E Second-line chemotherapy
two different chemotherapy regimens were compared. In 
one arm induction chemotherapy was followed by surgery 
and/or radiotherapy to the residual (if any) tumor and main­
tenance chemotherapy. Patients in the other arm started 
with more extensive surgery and/or radiation to the initial 
tumor, followed by the same maintenance therapy.
The long-term results showed no statistically signifi­
cant difference between the two arms, so that induction 
chemotherapy with a reduction in the complementary lo­
cal treatment had improved the quality of life without 
jeopardizing the survival rates.
On the basis of experience gained in the previous stud­
ies, the objectives of the 84 SIOP study were to improve 
the survival RMS by introducing ifosfamide in the chemo­
therapy and to minimize the sequelae of further treatment 
by limiting the local therapy, whether surgery or, espe­
cially, radiotherapy, with its severe late sequelae. The 89 
SIOP study tailored treatment more precisely by stratify­
ing patients according to stage and site.
Chemotherapy was further reduced in group A and B, 
with local therapy only in selected cases rather than sys­
temic chemotherapy. The present therapeutic scheme of 
the SIOP group, based on local tumor invasiveness, is 
shown in Table 7.
Results
Results obtained in the treatment of children with rhab­
domyosarcoma have improved dramatically in the last
few decades. The IRS reports an overall survival rate of 
81% for urogenital rhabdomyosarcoma in the first study. 
Relapse was seen within 2 years and long-term survival in 
this case was poor, with only 15%. In the second study the 
survival rates did not differ very much for all urogenital 
rhabdomyosarcomas. The 3-year relapse-free survival rate 
for PTRM remained excellent, with 93% for group I and 
90% for group II patients [13, 23, 24]. The third study 
showed a 3-year survival rate of 95% and a relapse-free 
survival rate of 89% over the same period for children with 
PTRM (all groups). The last figure remained stable at the 
5-year evaluation, again confirming that if relapse occurs 
this will be in the first early years after diagnosis [31],
The results of the SIOP Rhabdomyosarcoma group are 
comparable. Olive et al. report an overall survival rate of 
100% in a subset of 19 children with PTRM stage I in the 
first conducted study. The 3-year relapse-free survival in
18 patients (1 refused any therapy) was 78% [19]. The 
1984 SIOP study shows a 3-year survival rate of 72% for 
all rhabdomyosarcomas in all sites and in stages I, II and 
III (TNM classification), with a relapse-free 3-year sur­
vival of 53%. The 4-year survival rate for the PRTM 
group, with 88% was, slightly lower than that recorded in 
the IRS study over a similar period. The Germ an CWS 
studies showed a slightly better survival rate of 95%, 
whereas in Italy no patients in this group died [26], The 
results of the 1989 SIOP study shows an overall survival 
of 78% at 3 years, with excellent results, 94% survival, 
for group A and group B patients. For groups C and E the 
results were also good, with 2-year survival rates of 87% 
and 73%, respectively. The higher risk when the intensity 
of the local treatment is decreased was reflected in a 
higher relapse rate of 28% in groups B and C. The group 
that benefited the most from this protocol was group A, 
with an ultra-short chemotherapy treatment without alky­
lating agents [29],
Discussion
The improvement of the treatment results in children with 
rhabdomyosarcomas forces the specialists involved to 
look for further improvement of the quality of life without 
jeopardizing the final outcome. Evaluation went from rad­
ical, mostly mutulating excision without any adjunctive 
treatment at all to a combined modality of surgery, radio­
therapy and chemotherapy. All modalities have their price 
to be paid. This can be immediate, like the peri- and post­
operative morbidity in the case of surgery, or later as a re­
sult of cumulative toxic effects in the case of chemother­
apy, or more delayed after radiotherapy. Since tumor char­
acteristics have remained unchanged we only can tailor 
the treatment to the actual tumor type and site in a given 
individual. We have learned that urogenital rhabdomyo­
sarcomas have a good prognosis, especially PTRM. There­
fore, the general conclusions of the large studies involving 
all rhabdomyosarcomas need to be adapted and applied to
PTRM.
The fact that in 60% of the cases radical orchiectomy 
alone yields a 2-year survival rate of between 50% and 
60% is of great importance in this context [15, 20].
Lymph node involvement has been reported in between 
26% and 71% of cases [13, 24]. To avoid the bias of small 
number studies it is more adequate to look at the greater 
series reporting an incidence of almost 30%; [31]. Based 
on these data RPLND was recommended for all groups in 
IRS I, II and III and performed in the higher stages in the 
early SIOP studies.
The first workers to challenge the need for RPLND 
were Olive et al. [19] who in 1984 reported the results of 
a SIOP study (1971-1981) in which a subset (19 out of 
32) of children with PTRM was considered to belong to a 
good prognosis group on the basis of a radiological eval­
uation (intravenous pyelography and/or lymphangiogra­
phy) that showed neither gross nodal involvement nor 
distant metastasis. Treatment consisted in chemotherapy 
for 18 (up to 1977) or 8 (after 1977) months in 18 pa­
tients. In 1 case the child’s parents refused any therapy 
until a relapse occurred. In 17 patients relapse-free sur­
vival for more than 3 years was achieved. Two patients 
had relapses (1 without initial therapy) in the retroperi­
toneal space and 1 also locally. After this more authors 
supported the idea that the clinical node evaluation (CNE) 
with modem imaging techniques obviates the need for 
surgical node evaluation (SNE) [9, 22]. Others still advo­
cate RPLND at least for staging if not as a curative proce­
dure [1, 13,31].
This issue cannot be adequately judged without know­
ing how reliable the preoperative clinical staging really is. 
The published studies [9, 30, 31] involve a total of 141 
evaluable patients. (CT scan and lymphangiography are 
considered to be equally valuable.) The 141 patients in­
clude 122 for whom both clinical node evaluation (CNE) 
and pathological node evaluation (PNE) data are avail­
able.
In 102 patients the CNE and PNE outcome was equiv­
ocal. In 16 patients the CNE was false negative (11%) and 
in 4 patients the CNE was false positive (3%). The sensi­
tivity, meaning that CNE positivity is related to positive 
pathological findings in these studies, is not good, varying 
between 40% and 57%.
The specificity, meaning that negative pathological 
findings were recorded in the same patients as negative 
findings at clinical investigation, was much better, with 
over 90%. The relevance of the clinical data is more im­
portant, confronting us with a false-negative percentage of
11, meaning that in a group of 100 children judged nega­
tive on clinical screening, children 11 will have positive 
lymph nodes at the time of diagnosis. These figures are 
strikingly similar to those seen in the case of nonsemino- 
matous testicular germ-cell tumors [16].
So far all children with PTRM are treated at least with 
chemotherapy after the radical orchiectomy. For a small 
number of group I children (n = 24) this was the only 
treatment they received as clinical screening had been 
negative in these cases. Two children received no further 
treatment at all [19, 20, 22, 30]. All of these 26 children 
were alive after an interval of at least 3 years. There was 
no evidence of disease (NED) in 24 of them, while 2 (8%) 
had relapses in the retroperitoneal space; 1 of these chil­
dren had received no initial treatment at al. They both sur- 
vived after additional chemotherapy. ^
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If we assume a 11% false-negative rate on clinical 
screening in this group, at least 3 children should have 
had positive lymph nodes. It would be purely speculative 
to suggest that these would have been those who had 
retroperitoneal relapses.
Relapse in the retroperitoneal space after a complete 
RPLND only is very rare. In the largest study this oc­
curred in only 1 patient of 0.8% [31]. It was not reported 
in the other studies discussed, in which most children re­
ceived radiotherapy in addition. This too is remarkably 
compatible with data on the testicular germ cell tumors, 
in which retroperitoneal relapses after a selective RPLND 
occur in less than 2% of cases whereas in the population 
managed with surveillance alone the corresponding re­
lapse rate is about 30% [16]. The role of radiotherapy is 
difficult to judge in isolation from the RPLND, since ac­
cording to the protocols almost all children with lymph 
node involvement received radiotherapy. Relapses after 
radiotherapy with or without RPLND are also very rare. 
None was reported in one of the series used above.
There is no doubt that radiotherapy and RPLND are 
very effective in obtaining local tumor control. RPLND 
alone may be only slightly less effective (± 1%), but 
chemotherapy alone can also control this situation in over 
90% (see above). So the question as to what treatment 
carries the highest burden of late sequelae in children 
arises. Without any doubt it is obvious that radiotherapy 
causes the most severe late sequelae.
In a study of the delayed effects of multimodality ther­
apy in 18 patients with non-metastatic PTRM, Hughes et 
al. found short stature in 4 out of 9 children who had re­
ceived radiotherapy (2 died). Also a common bile duct 
stricture was seen following radiation therapy [12]. On 
the other hand, RPLND also had quite considerable (im­
mediate) consequences. Heyn et al. reported severe short­
term complications (bowel obstruction) in 8 of 74 patients 
who underwent RPLND. Eight patients had either a low 
volume or no antegrade ejaculation, including 2 who suf­
fered some erectile dysfunction. In 5 patients chronic 
lymphedema was found at the primary site [10]. Modem 
techniques have made RPLND a safer nerve-sparing tech­
nique, however, so that less than 20% of patients will be 
confronted with retrograde ejaculation and hardly any 
with bowel complications Lymphedema is no longer seen 
[16].
Thanks to such modem fertility-supporting techniques 
as intracytoplastmatic sperm injection (ICSI), later fertil­
ity after RPLND is no longer a possible cause of concern. 
The most commonly used chemotherapeutic agents are: 
vincristine, actinomycin, cyclophosphamide, ifosfamide 
and Adriamycin. All these agents have been followed by 
long-term sequelae. Ifosfamide has been connected with 
neurotoxicity [3]. We could demonstrate early after the 
start of ifosfamide in the treatment of rhabdomyosarcoma 
renal and tubular dysfunction, leading to a syndrome 
known as the Toni-Fanconi syndrome [2]. We have also 
noted severe long-term effects, such as growth retardation 
resulting from the renal and tubular dysfunction caused by 
ifosfamide (personal communication).
The IRS study demonstrated an increased risk for sec­
ondary acute myeloid leukemia in patients treated with
cyclophosphamide and an even more increased risk for 
patients treated with the same concentration of cyclophos­
phamide and etoposide [11]. Cardiomyopathy following 
Adriamycin is well known.
Moreover, the SIOP MMT-84 and MRT-89 studies 
have demonstrated that a large number of patients with 
PTRM have clinical stage I disease and that excellent sur­
vival can be attained in these patients without RPLND 
and with only minimal chemotherapy consisting of vin­
cristine and actinomycin D for 9 weeks, which does not 
have severe long-term sequelae.
Concluding remarks
The rarity of the PTRM in children makes close collabo­
ration between centers worldwide necessary. The good 
prognosis of this particular tumor means that great care 
must be taken to exclude the possibility that therapy might 
be more dangerous than the tumor itself. The striking simi­
larity with (stage I) non-seminomatous germ-cell tumors 
should be taken into consideration, especially as experi­
ence in the treatment of these germ-cell tumor is based on 
large numbers of patients. Their embryonal character 
means that they are more likely to show a closer similar­
ity to pediatric cancers with a higher degree of inherited 
genetic influence.
Obviously the need for supplementary therapy in tu­
mors clinically negative for node involvement is very lim­
ited, The most appropriate course seems to restrict both 
the duration and the toxicity of the chemotherapy admin­
istered after orchiectomy. All tumors with clinically posi­
tive nodes should have a highly selective RPLND for fur­
ther staging and therapy, after induction chemotherapy. In 
most cases, induction chemotherapy will result in nega­
tive histological findings after RPLND so that radiother­
apy is not needed. Radiotherapy can therefore be re­
stricted to the rare group of non-responders to chemother­
apy after RPLND.
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